How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
MD Anderson and Phoenix to advance cell and gene therapy tech
MD Anderson will have exclusive access to the new rimiducid formulation to be used with its inducible switch…
Health care CEO salaries, UnitedHealth’s busy week
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Join Sept. 18 with George Church and this year’s top biotech startups
I asked AI the other day how many biotechs have been co-founded by Harvard’s George Church. About 50…
Medicare Advantage research machine, A big home health deal
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Health Care Inc.: MAGA backs Medicare, faux drug price transparency
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
Medicare Savings Programs face cut, hospitals and insurers report Q2 results
Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
Where Are All the AI Drugs?
A new drug usually starts with a tragedy. Peter Ray knows that. Born in what is now Zimbabwe,…
FDA focuses attention on rejected drug decisions
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…